Author:
Kayode Tolulope Adeyemi,Addo Agyapong Kofi,Addison Thomas Kwame,Tweneboah Austine,Afriyie Stephen Opoku,Abbas Dawood Ackom,Seth Ayesha,Badu-Tawiah Abraham K.,Badu Kingsley,Koepfli Cristian
Abstract
Abstract
Background
Accurate diagnosis and timely treatment are crucial in combating malaria.
Methods
A total of 449 samples were screened for Plasmodium falciparum infection by expert microscopy, qPCR, and three RDTs, namely Rapigen Biocredit Malaria Ag Pf (detecting HRP2 and pLDH on separate bands), Abbott NxTek Eliminate Malaria Ag Pf (detecting HRP2), and SD Bioline Malaria Ag Pf (detecting HRP2). hrp2/3 deletion typing was done by digital PCR.
Results
45.7% (205/449) individuals tested positive by qPCR for P. falciparum with a mean parasite density of 12.5 parasites/μL. Using qPCR as reference, the sensitivity of microscopy was 28.3% (58/205), the Biocredit RDT was 52.2% (107/205), the NxTek RDT was 49.3% (101/205), and the Bioline RDT was 39.5% (81/205). When only samples with densities > 20 parasites/μL were included (n = 89), sensitivity of 62.9% (56/89) by microscopy, 88.8% (79/89) by Biocredit, 88.8% (79/89) by NxTek, and 78.7% (70/89) by Bioline were obtained. All three RDTs demonstrated specificities > 95%. The limits of detection (95% probability that a sample tested positive) was 4393 parasites/μL (microscopy), 56 parasites/μL (Biocredit, considering either HRP2 or pLDH), 84 parasites/μL (NxTek), and 331 parasites/μL (Bioline). None of the three qPCR-confirmed P. falciparum positive samples, identified solely through the pLDH target, or eight samples negative for all RDTs but qPCR-positive at densities > 20 parasites/µL carried hrp2/3 deletions.
Conclusion
The Biocredit and NxTek RDTs demonstrated comparable diagnostic efficacies. All three RDTs performed better than microscopy.
Funder
NIH
University of Notre Dame
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. WHO. World malaria report 2022. Geneva: World Health Organization; 2023. [Internet]. 2023 [cited 2024 Jun 26]. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023
2. WHO. Global Malaria program. Diagnostic Testing. [Internet]. Geneva: World Health Organization; 2021 [cited 2024 Jun 26]. https://www.who.int/teams/global-malaria-programme/case-management/diagnosis#:~:text=Prompt%20malaria%20diagnosis%20either%20by,and%20for%20strong%20malaria%20surveillance.
3. Niyukuri D, Sinzinkayo D, Troth EV, Oduma CO, Barengayabo M, Ndereyimana M, et al. Performance of highly sensitive and conventional rapid diagnostic tests for clinical and subclinical Plasmodium falciparum infections, and hrp2/3 deletion status in Burundi. PLoS Global Public Health. 2022;2: e0000828.
4. WHO. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 8 (2016–2018) [Internet]. Geneva: World Health Organization; 2018 [cited 2024 Jun 27]. https://www.who.int/publications/i/item/9789241514965
5. Houzé S, Boly MD, Le Bras J, Deloron P, Faucher JF. Pf HRP2 and Pf LDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J. 2009;8:211.